Abivax SA banner

Intrinsic Value

The intrinsic value of Abivax SA (2X1) under the Base Case is 21.82 EUR per share. Compared with the current market price of 81.6 EUR, the stock appears Overvalued by 73% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

2X1 Intrinsic Value
€21.82
Overvaluation 73%
Intrinsic Value
Price €81.6
Alert me when 2X1 is below its intrinsic value
Today €17.46 · 78.6% below the current price

2X1 is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alternatives to 2X1

Fundamental Analysis

What Abivax Does

Biotechnology Health Care

Abivax is a biotechnology company that develops drug candidates for inflammatory and immune-driven diseases. Its main work is research and clinical testing, especially for conditions like ulcerative colitis, where it is trying to turn its lead molecule into a prescription medicine. It is not a broad drug seller; it is a drug developer that owns and advances its own clinical programs.

Headquarters
France FR
Employees
80
IPO date
Jun 26, 2015
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Abivax SA

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

ABVX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one 2X1 stock?

The intrinsic value for Abivax SA (2X1) under the Base Case is 21.82 EUR.

Is 2X1 stock undervalued or overvalued?

Compared with the current market price of 81.6 EUR, the stock appears Overvalued by 73% .

Back to Top